NtrkA Immunohistochemical Expression in Papillary Thyroid Carcinoma: A Clinicopathological Study | ||
| SECI Oncology Journal | ||
| Volume 12, Issue 3, July 2024, Pages 317-323 | ||
| Abstract | ||
| Background: Neurotrophin receptors are becoming more widely recognized as potential cancer therapeutic targets, although their clinical and pathological implications in thyroid cancer remain unclear. Examining neurotrophic tyrosine receptor kinase (Ntrk) fusions in papillary thyroid carcinoma (PTC) patient cohorts has offered information on the genetic basis of thyroid cancer. Methods: This study included patients with PTC, thyroid adenoma, and multinodular goiter (MNG). The study aimed to investigate the association between the clinicopathological parameters and tropomyosin receptor kinase A (TrkA) expression in PTC patients and also to evaluate the immunohistochemical expression of TrkA in cases of thyroid adenoma and MNG, using immunohistochemistry streptavidin-biotin-technique. Results: This study comprised 77 cases in total, 27 cases with PTC, 13 with thyroid adenoma, and 37 cases with MNG, TrkA expression was not observed in adenoma or MNG cases, while expression was observed in 29.6% of PTC cases. TrkA expression differed significantly between instances of PTC, thyroid adenoma, and MNG (P<0.001). In PTC, there was a strong positive relationship between TrkA expression and T stage (P=0.002), lymph node involvement (P=0.004), and distant metastasis. There was no significant statistical difference in TrkA expression among patients based on their age or gender. Conclusion: TrkA expression is considered a negative prognostic marker, associated with tumor progression, advanced stages, and the presence of both lymph node and distant metastases, which may be valuable in assessing the aggressiveness of the tumor. TrkA could be a useful therapeutic target to reduce invasion and metastasis. | ||
| Keywords | ||
| NtrkA; PTC; Immunohistochemistry | ||
|
Supplementary Files
|
||
|
Statistics Article View: 21 |
||
